RVMD News

Levi & Korsinsky Urges Erasca, Inc. (ERAS) Shareholders to Act Before Lead Plaintiff Deadline August 10, 2026

ERAS LAWSUIT ALERT: Levi & Korsinsky Notifies Erasca, Inc. Investors - Lead Plaintiff Deadline August 10, 2026

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

ERAS ALERT: Securities Fraud Class Action Launched Against Erasca, Inc. - August 10, 2026 Deadline

Investor Alert: Deadline Approaching to Join Erasca, Inc. (ERAS) Class Action - Contact Levi & Korsinsky

Recover Investment Losses: Class Action Initiated Against Erasca, Inc. (ERAS)

Investor Alert: Deadline Approaching to Join Erasca, Inc. (ERAS) Class Action - Contact Levi & Korsinsky

Lost Money on Erasca, Inc. (ERAS)? Join Class Action Before August 10, 2026 - Contact Levi & Korsinsky

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Securities Fraud Class Action Filed Against Erasca, Inc. (ERAS) – Levi & Korsinsky Reminds Investors of August 10, 2026